LAVA intents to delist from Nasdaq [Seeking Alpha]
LAVA Announces Exceeding Minimum Condition in Tender Offer and Intent to Delist from Nasdaq
XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements [Yahoo! Finance]
XOMA GAAP EPS of $0.70 beats by $0.74, revenue of $9.35M misses by $2.12M [Seeking Alpha]
LAVA Therapeutics N.V. Shareholders are Reminded to Tender Shares for XOMA Royalty Transaction Before November 12, 2025 Deadline [Yahoo! Finance]